Regeneron Q2 FY26 GAAP EPS falls 5% to $12.23; revenue rises 17% to $4.3 billion
REGN•Guidance
2026 GAAP R&D guidance was tightened to $6.5-$6.64 billion.
Q2 results
Regeneron Q2 2026 revenue rose 17% to $4.29 billion; GAAP EPS slipped 5% to $12.23.
Non-GAAP EPS increased 11% to $14.29.
Collaboration and product sales
Sanofi collaboration revenue climbed 51% to $2.17 billion on higher antibody commercialization profits tied to Dupixent sales.
U.S. EYLEA HD net sales jumped 52% to $596 million; U.S. EYLEA net sales fell 45% to $412 million.
Libtayo global net sales increased 30% to $489 million; Dupixent global net sales, recorded by Sanofi, rose 38% to $6 billion.
